ALX Oncology Holdings Inc. Files 8-K Report
Ticker: ALXO · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1810182
Sentiment: neutral
Topics: sec-filing, financials, operations
Related Tickers: ALXO
TL;DR
ALXO filed an 8-K on Aug 8th covering financials and operations - check the full report for details.
AI Summary
On August 8, 2024, ALX Oncology Holdings Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that ALX Oncology Holdings Inc. is providing updates on its financial condition and operations to the SEC. Investors should review the full filing for details on performance and any significant developments.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial results or operational news that would indicate a change in risk.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- August 8, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by ALX Oncology Holdings Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of August 8, 2024.
What is the Commission File Number for ALX Oncology Holdings Inc.?
The Commission File Number for ALX Oncology Holdings Inc. is 001-39386.
Where are ALX Oncology Holdings Inc.'s principal executive offices located?
The principal executive offices of ALX Oncology Holdings Inc. are located at 323 Allerton Avenue, South San Francisco, California 94080.
What is the Standard Industrial Classification (SIC) code for ALX Oncology Holdings Inc.?
The Standard Industrial Classification (SIC) code for ALX Oncology Holdings Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-08 16:08:01
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20240808.htm (8-K) — 47KB
- alxo-ex99_1.htm (EX-99.1) — 152KB
- img62044099_0.jpg (GRAPHIC) — 145KB
- 0000950170-24-093930.txt ( ) — 515KB
- alxo-20240808.xsd (EX-101.SCH) — 25KB
- alxo-20240808_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated August 8, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: August 8, 2024 By: /s/ Peter Garcia Peter Garcia Chief Financial Officer 2